Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Sofosbuvir for previously untreated chronic hepatitis C infection.
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Telaprevir for retreatment of HCV infection.
Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase.
Boceprevir for previously treated chronic HCV genotype 1 infection.
The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virologic response in previously treated patients with chronic HCV genotype 1 infection, as compared with pegintersfer on-off therapy alone.
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
- J. McHutchison, E. Lawitz, M. Sulkowski
- Medicine, BiologyThe New England journal of medicine
- 10 December 2009
In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between theTwo available peginterferon-ribavirin regimens or between the two doses of pegin terferon alfa-2b.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive…
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Leadipasvir-sofosbuvir for 8 weeks was associated with a high rate of sustained virologic response among previously untreated patients with HCV genotype 1 infection without cirrhosis, and results indicated noninferiority of the 8-week ledipas Viral-SofosBuvir regimen.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologyic response to prior interferon-based treatment.